Analytical Lens: Exploring Cytokinetics Inc (CYTK)’s Financial Story Through Ratios

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The closing price of Cytokinetics Inc (NASDAQ: CYTK) was $48.51 for the day, down -1.24% from the previous closing price of $49.12. In other words, the price has decreased by -$1.24 from its previous closing price. On the day, 2.5 million shares were traded. CYTK stock price reached its highest trading level at $49.36 during the session, while it also had its lowest trading level at $48.04.


Our analysis of CYTK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.19 and its Current Ratio is at 7.19.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.

On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.

On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 07 ’24 when Malik Fady Ibraham sold 15,547 shares for $65.11 per share. The transaction valued at 1,012,265 led to the insider holds 137,056 shares of the business.

HENDERSON JOHN T sold 10,562 shares of CYTK for $681,671 on Apr 25 ’24. The Director now owns 32,070 shares after completing the transaction at $64.54 per share. On Apr 09 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 32,605 shares for $74.31 each. As a result, the insider received 2,422,918 and left with 138,567 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 5613237248 and an Enterprise Value of 5222420480. For the stock, the TTM Price-to-Sale (P/S) ratio is 1483.24. Its current Enterprise Value per Revenue stands at 1391.903 whereas that against EBITDA is -10.755.

Stock Price History:

Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is -25.00%, while the 200-Day Moving Average is calculated to be -10.62%.

Shares Statistics:

CYTK traded an average of 2.22M shares per day over the past three months and 3771440 shares per day over the past ten days. A total of 114.66M shares are outstanding, with a floating share count of 110.47M. Insiders hold about 3.65% of the company’s shares, while institutions hold 101.17% stake in the company. Shares short for CYTK as of 1715731200 were 14191794 with a Short Ratio of 6.40, compared to 1713139200 on 14042444. Therefore, it implies a Short% of Shares Outstanding of 14191794 and a Short% of Float of 22.11.

Most Popular